You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab

Price: EUR 27.50